NEW YORK (GenomeWeb News) - Iconix Pharmaceuticals today said it will use its in vitro toxicogenomic technology to assess drug safety for Merck in the early states of pre-clinical development.
 
Iconix's in vitro database includes gene-expression profiles on 119 compound treatments on primary rat hepatocytes.
 
Financial details were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.